Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)

Sponsor
Russian Academy of Medical Sciences
Study ID
NCT01676506
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Genetic factors of an individual patient may have an impact on Ranibizumab (Lucentis) treatment outcome in patients with Wet Age-Related Macular Degeneration (AMD).

Key Dates

First listed
Aug 31, 2012
Start date
Oct 31, 2011
Status verified
Aug 2012
Primary completion
Oct 31, 2013
Completion
Oct 31, 2015

Study Design

Enrollment
300 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Visual acuity [ Time Frame: Baseline and month 3 ]

Central Contacts

Related Studies